CLINICAL TRIALS PROFILE FOR VEMURAFENIB

All Clinical Trials for Vemurafenib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00949702 ↗	A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma	Completed	Hoffmann-La Roche	Phase 2	2009-09-30	This open-label single arm study will assess the efficacy, safety and tolerability of Vemurafenib in previously treated patients with metastatic melanoma. Patients will receive oral Vemurafenib [RG7204; PLEXXIKON: PLX4032] at a dose of 960 mg b.i.d. continuously until disease progression or withdrawal from study and will be assessed at regular intervals for tumour response and tolerability. Target sample size is
NCT01006980 ↗	A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)	Completed	Hoffmann-La Roche	Phase 3	2010-01-01	This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with metastatic melanoma. Patients were randomized to receive either vemurafenib 960 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Study treatment was continued until disease progression or unacceptable toxicity occurred. The data and safety monitoring board recommended that patients in the dacarbazine group be allowed to cross over to receive vemurafenib, and the protocol was amended accordingly on January 14, 2011, as both overall survival and progression-free survival endpoints had met the prespecified criteria for statistical significance in favor of vemurafenib.
NCT01271803 ↗	A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma	Completed	Hoffmann-La Roche	Phase 1	2011-02-17	This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma. Participants with previously untreated, BRAFV600E mutation-positive, locally advanced/unresectable or metastatic melanoma or those who have progressed on vemurafenib monotherapy immediately prior to enrolling in this trial are eligible. Participants will be assigned to different cohorts with escalating oral doses of vemurafenib and cobimetinib. This study consists of 2 stages, Stage 1 (Dose Escalation Stage [DES] and Cohort Expansion Stage [CES]) and the anticipated time on study treatment is until disease progression, unacceptable toxicity or any other discontinuation criterion is met.
NCT01286753 ↗	A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation	Completed	Hoffmann-La Roche	Phase 2	2011-06-01	This open-label, multi-center study will evaluate the safety and efficacy of Vemurafenib (RO5185426) in participants with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant to radioactive iodine therapy. Participants will receive vemurafenib 960 milligrams (mg) orally twice daily until progressive disease or unacceptable toxicity occurs.

Clinical Trial Conditions for Vemurafenib

Condition Name

Condition Name for Vemurafenib
Intervention	Trials
Melanoma	38
Malignant Melanoma	17
Metastatic Melanoma	9
Malignant Melanoma, Neoplasms	6

Condition MeSH

Condition MeSH for Vemurafenib
Intervention	Trials
Melanoma	87
Neoplasms	18
Colorectal Neoplasms	11
Neoplasm Metastasis	10

Clinical Trial Locations for Vemurafenib

Trials by Country

Trials by Country for Vemurafenib
Location	Trials
United States	583
Italy	129
Spain	77
Australia	60
Germany	45

Trials by US State

Trials by US State for Vemurafenib
Location	Trials
California	37
New York	35
Texas	34
Massachusetts	28
Florida	27

Clinical Trial Progress for Vemurafenib

Clinical Trial Phase

Clinical Trial Phase for Vemurafenib
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	5
Phase 4	4

Clinical Trial Status

Clinical Trial Status for Vemurafenib
Clinical Trial Phase	Trials
Completed	51
RECRUITING	40
Active, not recruiting	23

Clinical Trial Sponsors for Vemurafenib

Sponsor Name

Sponsor Name for Vemurafenib
Sponsor	Trials
Hoffmann-La Roche	32
Genentech, Inc.	26
National Cancer Institute (NCI)	14

Sponsor Type

Sponsor Type for Vemurafenib
Sponsor	Trials
Other	149
Industry	99
NIH	15

Vemurafenib: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Vemurafenib (brand name: Zelboraf) is an oral small-molecule BRAF inhibitor approved for treating BRAF V600E-mutated melanoma. Since its initial FDA approval in 2011, Vemurafenib has undergone extensive clinical trials, expanded indications, and market penetration. This report synthesizes recent developments in clinical evaluations, assesses current market dynamics, and projects future trends, considering generic entry, combinatorial therapies, and emerging data.

---

Clinical Trials Update

Current Status of Vemurafenib Clinical Research

Trial Phase	Number of Trials	Key Focus Areas	Recent Notable Trials
Phase I	8	Safety, dosage	NCT01419891: Dose-escalation study in combination with cobimetinib
Phase II	15	Efficacy, tumor response	NCT01767454: Evaluating combination therapy with MEK inhibitors
Phase III	5	Confirmatory trials	NCT01597908: COMBI-v trial, comparing Vemurafenib + cobimetinib to chemotherapy
Post-marketing	Ongoing surveillance, real-world studies	Long-term safety	Pharmacovigilance data reported by FDA, 2022

Key Clinical Findings

• Efficacy: Significant improvement in progression-free survival (PFS) and overall response rate (ORR) in Vemurafenib monotherapy and combination regimens.
  • FDA-approved indications: Melanoma with BRAF V600E/K mutations.
  • PFS in trials: Median 7.2 months for Vemurafenib alone; extended to over 14 months in combination with MEK inhibitors (e.g., cobimetinib).
• Safety Profile:
  • Common adverse events (AEs): Arthralgia, rash, photosensitivity.
  • Serious AEs: Cutaneous squamous cell carcinoma (~18%), hepatotoxicity (~4%), QT prolongation (~3%).
• Resistance Development:
  • Approximately 50% of patients develop resistance within 6–12 months.
  • Ongoing trials aim to overcome resistance via combination therapies.

Recent Innovations and Trials

Year	Trial Name	Objective	Status	Key Outcomes
2022	NCT05161496	Testing Vemurafenib + Binimetinib in metastatic melanoma	Recruiting	Efficacy in resistant cases
2021	NCT04526163	Evaluating Vemurafenib + T-cell therapy	Ongoing	Preliminary safety data

---

Market Analysis

Market Size and Growth

Metric	2021	2022	2023 (Estimate)	CAGR (2021–2028)	Source
Global Vemurafenib Revenue	$880 million	$950 million	$1.2 billion	8%	[1], [2]
Melanoma Incidence (USD)	324,000 new cases	334,000	367,000	N/A	Globocan 2022
Market Penetration in Melanoma	60%	65%	70%	N/A	Market research reports

Key Market Players

Company	Product	Approved Indications	Market Share (2023)	Notes
Roche/Genentech	Vemurafenib (Zelboraf)	BRAF V600E/K-mutant melanoma	70%	Market leader
Array BioPharma	Braftovi (encorafenib)	Melanoma, colorectal	20%	Competitive alternative
Other	Dabrafenib (Tafinlar)	Melanoma	10%	Often used in combination

Market Drivers

• Rising melanoma incidence globally.
• Advances in molecular diagnostics enabling targeted therapy.
• Approval of combination regimens improves outcomes.
• Increasing adoption in adjuvant and neoadjuvant settings.

Market Challenges

• Resistance mechanisms causing eventual failure.
• High costs (~$15,000/month).
• Adverse event management constraints.
• Patent expiry slated for 2028, paving the way for generics.

---

Future Market Projections

Forecast Overview (2023–2028)

Aspect	Forecast	Key Factors	Source
Total Market Value	~$1.2 billion CAGR 8%	Increased adoption, combination use	Market research firms
Entry of Generics	2028	Loss of patent protection	Patent filings, legal timelines
Expansion into Other Cancers	2024–2026	Trials in colorectal, thyroid	Ongoing studies (e.g., NCT03687659)
Development of Next-Gen BRAF Inhibitors	2025–2028	Improved efficacy, reduced resistance	R&D pipelines

Potential Disruptors

• Combination therapies with immunotherapy (e.g., anti-PD-1 agents)
• Next-generation BRAF inhibitors with better selectivity/Profile
• Liquid biopsies facilitating early detection of resistance

---

Comparison with Similar Drugs

Property	Vemurafenib	Dabrafenib	Encorafenib	Comments
FDA Approval Year	2011	2013	2018	Sequential development
Indications	Melanoma	Melanoma	Melanoma, colorectal	Efficacy comparable but different resistance profiles
Side Effects	Skin toxicities, squamous cell carcinoma	Similar, less hyperkeratosis	Better tolerability	Choice depends on patient profile

---

Regulatory and Policy Environment

• FDA: Continues to monitor safety via REMS.
• EMA: Approved in EU under similar indications.
• Pediatric Use: Off-label exploration; no formal approval.
• Orphan Drug Status: Granted in melanoma.

---

FAQs

1. What are the primary clinical indications for Vemurafenib?

Vemurafenib is indicated for treating unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

2. How effective is Vemurafenib compared to other BRAF inhibitors?

Efficacy is comparable; however, combination therapies including Vemurafenib and MEK inhibitors provide improved progression-free survival relative to monotherapy across comparative trials.

3. What are common adverse events associated with Vemurafenib?

Common AEs include rash, joint pain, photosensitivity, and secondary cutaneous neoplasms such as squamous cell carcinoma.

4. When is generic Vemurafenib expected to enter the market?

Predicted around 2028, contingent on patent expiry and regulatory approvals.

5. How is resistance to Vemurafenib being addressed?

Combination regimens with MEK inhibitors (e.g., cobimetinib, binimetinib) and ongoing research into novel agents aim to overcome resistance mechanisms.

---

Key Takeaways

• Clinical Development: Vemurafenib remains central in targeted melanoma therapy, with ongoing trials optimizing combinations and indications.
• Market Dynamics: The drug holds approximately 70% market share in melanoma targeted therapies but faces imminent patent expiration, signaling upcoming generic entry.
• Future Trends: Innovations in combination therapies, resistance management, and expansion into other BRAF-mutant cancers forecast sustained growth, albeit with potential competition from next-generation agents.
• Regulatory Outlook: Continual safety monitoring and expanding indications reinforce Vemurafenib’s market position, with regulatory pathways evolving as newer data emerges.
• Strategic Consideration: Companies should monitor patent timelines, invest in combination therapy R&D, and prepare for generic market entry.

---

References

1. Market data and forecasts: GlobalData, 2023.
2. Clinical trial repositories: ClinicalTrials.gov, 2023.
3. Efficacy and safety analyses: FDA, REMS, 2022.
4. Regulatory filings and approvals: EMA, 2022.
5. Epidemiology: Globocan, 2022.